

**Minutes of the Lancashire Medicines Management Group Meeting  
Held on Thursday 12 December 2013 at Preston Business Centre**

**PRESENT**

Dr Tony Naughton (TN)	Chair of LMMG	Lancashire CCG Network
Christine Woffindin (CW)	Medicines Information Manager	East Lancashire Hospitals NHS Trust
Dr Catherine Fewster (CF)	Chief Pharmacist	Lancashire Care NHS Foundation Trust
Kenny Li (KL)	Senior Manager – Medicines Optimisation	NHS Lancashire North CCG
Melanie Preston (MP)	Assistant Director - Medicines Optimisation	NHS Blackpool CCG
Lisa Rogan (LR)	Head of Medicines Commissioning	NHS East Lancashire CCG and NHS Blackburn with Darwen CCG
Louise Winstanley (LW)	Lead Pharmacist	NHS Fylde and Wyre CCG
Dr Kamlesh Sidhu (KS)	GP Prescribing Lead	NHS Lancashire North CCG
Nicola Baxter (NB)	Head of Medicines Optimisation	NHS West Lancashire CCG
Pauline Bourne (PB)	Senior Pharmacist, Medicines Management, Deputy Chief Pharmacist	University Hospitals of Morecambe Bay NHS Foundation Trust
Nicola Schaffel – on behalf of Julie Landale	Medicines Optimisation Lead Pharmacist	NHS Greater Preston CCG and NHS Chorley and South Ribble CCG

**IN ATTENDANCE:**

Elaine Johnstone (EJ)	Senior Executive – Medicines Management	NHS Staffordshire and Lancashire CSU
Brent Horrell (BH)	Head of Medicines Commissioning	NHS Staffordshire and Lancashire CSU
Julie Lonsdale (JLon)	Head of Medicines Performance	NHS Staffordshire and Lancashire CSU
Warren Linley (WL)	Senior Medicines Commissioning Pharmacist	NHS Staffordshire and Lancashire CSU
Jane Johnstone (Minutes)	Administrator	NHS Staffordshire and Lancashire CSU

ITEM	<u>SUMMARY OF DISCUSSION</u>	ACTION
2013/163	<p><b><u>WELCOME &amp; APOLOGIES FOR ABSENCE</u></b> The Chair welcomed everyone to the meeting.</p> <p><b>Apologies for absence</b> were noted on behalf of Alastair Gibson, Dr Emile Li Kam Wa, Dr Sakthi Karunanithi, Dr David Shakespeare, Dr Pervez Muzaffar, Dr Sigrun Baier and Dr Tom Marland.</p>	
2013/164	<p><b><u>DECLARATIONS OF INTEREST PERTINENT TO AGENDA</u></b> None</p>	
2013/165	<p><b><u>DECLARATION OF ANY OTHER URGENT BUSINESS</u></b> None</p>	
2013/166	<p><b><u>MINUTES OF THE LAST MEETING – 14<sup>th</sup> November 2013</u></b> The minutes of the meeting held on 14<sup>th</sup> November 2013 were agreed as a true and accurate record.</p>	

	<p>Updates from the action points (form the last meeting)</p> <p><i>2013/150 Melatonin</i></p> <ul style="list-style-type: none"> <li>- Obtain Shared care protocols that exist in Cumbria - provide process documents from Lancashire Care FT and prescribing data <b>Update:</b> CF has provided Lancashire Care prescribing data, the other actions are still on-going due to tight timescales.</li> <li>- Prescribing data required from acute trusts <b>Update:</b> DS has passed this to Gareth Price</li> <li>- Provide Mersey leaflet <b>Update:</b> The leaflet did not contain the information that was required; NB to circulate to all.</li> </ul> <p><i>2013/160 Lancashire RAG List Harmonisation</i></p> <ul style="list-style-type: none"> <li>- Review the document and feedback any amendment to local decisions to the CSU <b>Update:</b> This is on-going, feedback has not been received from all CCGs – to be reviewed in January.</li> </ul> <p>All other action points were implemented within the agreed timescales.</p> <p>JL reminded LMMG members to be mindful when amending and putting information on local websites that the most up to date guidelines can be found on the LMMG website.</p> <p>EJ informed LMMG members that if the guidelines change these will be emailed out to the group at the same point as being updated on the website.</p>	<p><b>PB/CF</b></p> <p><b>NB</b></p> <p><b>CCG Med Man Leads</b></p>
<p><b>2013/167</b></p>	<p><b><u>MATTERS ARISING (NOT ON THE AGENDA)</u></b></p> <p>There were no matters arising.</p>	
<p><b>2013/168</b></p>	<p><b><u>GOLIMUMAB – MODERATE TO SEVERE ULCERATIVE COLITIS</u></b></p> <p>WL gave an overview of the draft new medicine recommendation for consultation to the LMMG group and discussed the trials involved. It was noted that 5 CCGs had not responded to the consultation and therefore a decision was unable to be made today. In light of this, TN suggested extending the consultation period to January 2014. (Timescales of consultation periods was also discussed under item 2013/173).</p> <p><b><u>Action:</u></b> Extend the consultation period for Golimumab to January 2014. CSU Core Medicines Management Team to re-circulate the consultation documents highlighting the extended consultation period to those organisations that had not yet responded.</p>	<p><b>BH/WL</b></p>
<p><b>2013/169</b></p>	<p><b><u>LMMG – NEW MEDICINE REVIEWS WORK PLAN UPDATE</u></b></p> <p>BH presented the work plan to support the committee in prioritising medicines for review through LMMG. The COPD new medicines reviews have been drafted and will be circulated for consultation in time to be brought to the February LMMG meeting. BH informed the group that a request for nicotine strips has been received for use in smoking cessation services supported through Lancashire Care. It was highlighted that this would result in on-going prescribing and supply in primary care. It was also highlighted that Public Health would need to be engaged with for this piece of work due to the inter-relationship with community pharmacy voucher schemes; Janet Walton was suggested as an appropriate contact. It was agreed to add nicotine strips to the LMMG work plan.</p> <p><b><u>Action:-</u></b> Add nicotine strips to the LMMG work plan.</p>	<p><b>BH</b></p>

<p>2013/170</p>	<p><b><u>HORIZON SCANNING QUARTER 4 2013-14</u></b></p> <p>BH gave an overview of the Horizon Scanning Quarter 4 paper. BH gave the following updates:-</p> <ul style="list-style-type: none"> <li>• Golimumab – Ulcerative Colitis – to be considered at the January meeting (discussed under 2013/168).</li> <li>• Canagliflozin Type 2 Diabetes – this will be put out to consultation within the next few days once pricing information has been received.</li> <li>• Lubiprostone – Chronic Idiopathic Constipation – LMMG agreed to add this to the work plan due to it being a common condition managed by GPs.</li> <li>• Indacaterol/glycopyronium – COPD – this is on the work plan to discuss at the February 2014 LMMG.</li> <li>• Alogliptin – Type 2 Diabetes – LMMG agreed to add this to the work plan.</li> <li>• Lurasidone – Schizophrenia – CF will look into this further and bring back to the LMMG if it is to be recommended for the Lancashire Care formulary.</li> <li>• Dapagliflozin/metformin – Type 2 Diabetes – a decision was made not to add this to the work plan; this will be included in the Diabetes Guidelines work.</li> <li>• Eltrombopag – Thrombocytopenia (associated with Hep C) – there is on-going debate with NHS England regarding the responsible commissioner. A decision was made to provisionally add this to the work plan.</li> </ul> <p>Aripiprazole Depot - CF highlighted that aripiprazole depot was to be launched early in 2014. Lancashire Care Trust are in the process of looking into its possible place in therapy, it was agreed that if LCFT identify an appropriate place in therapy that it would then come to LMMG for consideration.</p> <p><b><u>Action:</u></b> Add lubiprostone, alogliptin and eltrombopag to the LMMG work plan. LCFT to Investigate lurasidone further.</p> <p>Include Dapagliflozin/metformin with the Diabetes Guidelines work.</p>	<p>BH</p> <p>CF</p> <p>BH</p>
<p>2013/171</p>	<p><b><u>NEW NICE TECHNOLOGY APPRAISAL GUIDANCE FOR MEDICINES NOVEMBER 2013</u></b></p> <p>EJ gave an overview of new NICE Technology Appraisal Guidance for the five published in November 2013. EJ talked through the proposed traffic light recommendations for the relevant medicines. It was noted that a column has been added to the table to identify where a Blueteq form is required when NICE guidance is approved. The CSU team will begin to create Blueteq forms as part of this work from now on.</p> <p><b><u>Actions:</u></b> Add ranibizumab for the treatment of choroidal neovascularisation to the website as RED in line with NICE TA 298 and develop a Blueteq form Add bosutinib for the treatment of leukaemia to the website as BLACK in line with NICE TA 299 Add peg interferon alfa and ribavirin for the treatment of Hepatitis C to the website as RED in line with NICE TA 300 Add fluocinolone for the treatment of Diabetic Macular Oedema to the website as RED in line with NICE TA 301 and develop a Blueteq form Add canakinumab for the treatment of Juvenile idiopathic arthritis to the website as BLACK in line with NICE TA 302. It was noted that NHS England are the responsible commissioner until patients exit childrens' services.</p>	<p>JLon</p>
<p>2013/172</p>	<p><b><u>NEW NHS ENGLAND MEDICINES COMMISSIONING POLICIES NOVEMBER 2013</u></b></p> <p>No NHS England commissioning policies were published this month. BH noted for information that NHS England has published a number of policies for Direct Commissioning Services pertaining to the Armed Forces/Prison Service. These may be helpful for CCGs when making local policy decisions.</p>	

2013/173	<p><b><u>PROPOSED CHANGE TO LENGTH AND SCHEDULING OF LMMG CONSULTATION PERIODS</u></b></p> <p>After a review of the current 2-week consultation period for draft LMMG products it was identified that the period was not long enough to enable CCGs and local decision making groups to consider these in advance of the consultation closing date. EJ discussed the outline of a proposed consultation schedule, recommending a 5 week consultation period. LMMG agreed with the recommendation to extend the consultation period to 5 weeks.</p> <p>TN suggested that an annual review of activity could take place at the January LMMG meeting. The Core CSU Medicines Management Team are to bring a paper to the January meeting summarising work undertaken/achievements/reflections over this period.</p> <p><b><u>Action:-</u></b> Change consultation period from 2 weeks to 5 weeks.</p> <p>A paper to be drafted for the January meeting summarising work undertaken / achievements / reflections.</p>	BH / JLon Core CSU MM Team
2013/174	<p><b><u>DENOSUMAB INFORMATION LEAFLET</u></b></p> <p>JLon discussed the Denosumab information sheet which had been developed in Lancashire North. JLon informed the group of the changes that have been made to the information sheet, as part of a review, detailed in the paper. A discussion took place regarding the administration of injections of Denosumab and whether a shared care document would be more useful.</p> <p><b><u>Action:-</u></b> Investigate background information to how this is currently used across Lancashire with a view to shared care guidelines.</p>	JLon
2013/175	<p><b><u>AFLIBERCEPT NICE TA UPDATE</u></b></p> <p>WL talked through the aflibercept NICE TA 294 update which was brought to the meeting for information. WL discussed the correspondence from NICE which was sought due to a lack of clarity on whether the TA covered sequential use of aflibercept in patient who had previously been treated with ranibizumab. JLon gave an update from her recent meeting with a consultant.</p> <p>A meeting with the Ophthalmology group is set up for January to discuss this further. The work around tariff costs will be picked up by the CSU contracting team. JLon has some information on tariffs; however, further investigation is required to clarify the difference between a day case patient and an out-patient.</p> <p>A discussion took place about the availability and completion of Blueteq forms. LMMG were advised that ophthalmology forms are on the system and are available for completion by clinicians.</p>	
2013/176	<p><b><u>LANCASHIRE SHARED CARE GUIDELINES</u></b></p> <p>JLon gave an update around the current situation with Shared Care Guidelines across Lancashire. A lengthy discussion took place and it was decided that CCG MM Leads will prioritise SCGs on a Lancashire wide basis and bring back to the February meeting. It was identified that an extra column will be added to the guideline table to identify priorities. JLon to action this and resend.</p> <p><b><u>Action:-</u></b> Add an extra column to the guidelines table to identify priorities/email out</p> <p>Prioritise SCGs on a Lancashire wide basis for the February meeting.</p>	JLon CCG MM Leads

2013/177	<p><b><u>LMMG – GUIDELINES WORK PLAN UPDATE</u></b></p> <p>Julie gave an update of the LMMG Guidelines work plan. An update of the on-going guidelines was shared below:-</p> <ul style="list-style-type: none"> <li>• Asthma guidelines – this work is on-going, it has been sent out to CCGs and is awaiting comments.</li> <li>• COPD guidelines – to be taken to the February meeting.</li> <li>• Specials alternative document – this will be brought to the March meeting.</li> <li>• Treatment of Juvenile Idiopathic Arthritis – to be discussed further at the next rheumatology alliance meeting.</li> <li>• Diabetes Guidelines – this is a high priority and new drugs are coming to the market</li> <li>• PPI Information – LW said that this is on-going.</li> <li>• ADHD GP Assessment documents – this was taken to the Commissioning Group; waiting to hear from Sonya.</li> <li>• Non-cancer pain guidelines – this is on-going.</li> <li>• Omega-3 fatty acid compounds – an update was requested based on the NICE guidelines for MI; position statement to be updated and brought back to January meeting.</li> </ul> <p><b><u>Action:-</u></b> Add above items to the January/February/March agendas</p>	JLon
----------	--	------

**Date and time of the next meeting**  
Thursday 9<sup>th</sup> January 2014 9.30 am to 11.30 am, Meeting Room 2 Preston Business Centre

**ACTION SHEET FROM THE  
LANCASHIRE MEDICINES MANAGEMENT GROUP  
THURSDAY 14 November & 12 December 2013**

<b>MINUTE NUMBER</b>	<b>DESCRIPTION</b>	<b>ACTION</b>	<b>DATE</b>
<b>2013/166</b>	<p><i>2013/150 Melatonin</i> Shared care protocols that exist in Cumbria - provide process documents from Lancashire Care FT and prescribing data <b>Update:</b> This matter is still on-going due to tight timescales.</p> <p>Provide Mersey leaflet <b>Update:</b> The leaflet did not contain the information that was required; NB to circulate to all.</p> <p><i>2013/160 Lancashire RAG List Harmonisation</i> Review the document and feedback any amendment to local decisions to the CSU <b>Update:</b> This is on-going, feedback has not been received from all CCGs – to be reviewed in January.</p>	<p>PB/CF</p> <p>NB</p> <p>CCG Med Man Leads</p>	<p>9<sup>th</sup> January 2014</p> <p>9<sup>th</sup> January 2014</p> <p>9<sup>th</sup> January 2014</p>
<b>2013/168</b>	<p><b><u>GOLIMUMAB – MODERATE TO SEVERE ULCERATIVE COLITIS</u></b> Extend the consultation period for Golimumab to January 2014</p>	BH/WL	19 <sup>th</sup> December 2013
<b>2013/169</b>	<p><b><u>LMMG – NEW MEDICINE REVIEWS WORK PLAN UPDATE</u></b> Add NRT products to the LMMG work plan.</p>	BH	19 <sup>th</sup> December 2013
<b>2013/170</b>	<p><b><u>HORIZON SCANNING QUARTER 4 2013-14</u></b> Add Lubiproston, Alogliptin and Eltromobopag to the LMMG work plan.</p> <p>Investigate Lurasidone/Schizophrenia further and bring back to the LMMG if it is to go on the Lancashire Care formulary. Include Dapagliflozin/Metformin with the Diabetes Guidelines work.</p>	<p>BH</p> <p>CF</p> <p>BH</p>	19 <sup>th</sup> December 2013
<b>2013/171</b>	<p><b><u>NEW NICE TECHNOLOGY APPRAISAL GUIDANCE FOR MEDICINES NOVEMBER 2013</u></b> Add ranibizumab to website as RED for TA298 and develop a Blueteq form Add bosutinib to website as black for TA299 for information Add peg interferon alfa TA300 to website for new indication for information Add fluocinolone to website for TA 301 as RED and develop a Blueteq form Add canakinumab to website for TA 302 as Black for information</p>	JLon	19 <sup>th</sup> December 2013
<b>2013/173</b>	<p><b><u>CHANGE TO LENGTH AND SCHEDULING OF LMMG CONSULTATION PERIODS</u></b> Change consultation period from 2 weeks to 5 weeks.</p> <p>A paper to be drafted for the January meeting</p>	BH/WL	All future consultations

	summarising work undertaken / achievements / reflections.	BH / JLon	9 <sup>th</sup> January 2014
2013/176	<p><b><u>LANCASHIRE SHARED CARE GUIDELINES</u></b> Add an extra column to the guidelines table to identify priorities/email out</p> <p>Prioritise SCG's on a Lancashire wide basis for the February meeting.</p>	<p>JLon</p> <p>All MM Leads</p>	<p>19<sup>th</sup> December</p> <p>13<sup>th</sup> February 2014</p>
2013/177	<p><b><u>LMMG – GUIDELINES WORK PLAN UPDATE</u></b> Add items to the January / February agenda</p>	JLon	9 <sup>th</sup> January & 13 <sup>th</sup> February 2014